Summary

iX Biopharma reported a lower net loss of $2.06 million for 1HFY2026, a 67% improvement year-over-year, driven by a favorable exchange rate. Revenue declined 14% due to lower demand for medicinal cannabis manufacturing services, but gross margin improved to 26%.

https://www.theedgesingapore.com/capital/results/ix-biopharma-reports-lower-net-loss-1hyf2026